Board Members Key Consultants Company News The Amazing Disappearing Stent, NIBIB, September 2004 Surviving as a Start-up, Red Herring Magazine, February 2006

Board Members

Bob Stockman is Chairman of the Board of REVA Medical and provided the initial startup capital after the Company's founder and angel investors began operations. Mr. Stockman has supported the Company financially and has provided overall strategic and operating guidance to REVA since its inception. He is also the President and founder of Group Outcome LLC in Princeton, NJ. Group Outcome is a merchant banking firm which deploys its capital and that of its financial partners in health care leveraged buyout transactions and medical device startups. His partners and he have been the founders and CEOs of 16 successful medical products companies. Mr. Stockman received his MBA from The Amos Tuck School at Dartmouth and his Bachelors degree from Harvard College.

Brian Dovey is a Managing Director of Domain Partners, a leading health care venture capital firm. Prior to joining Domain, Mr. Dovey was President and Chief Operating Officer of Rorer Group, a NYSE pharmaceutical and medical device company, which was later acquired by Rhone Poulenc. Mr. Dovey earned his MBA from Harvard Business School and his undergraduate degree at Colgate University.

Gordie Nye is a Managing Director of Group Outcome, LLC and a General Partner of Prism Ventures and was previously CEO of the Company. Mr. Nye previously headed-up two former Johnson & Johnson divisions, "A" Company Orthodontics and Critikon, after they were acquired in management buyouts. Earlier, he held senior marketing and management positions at Gillette and Reebok. Mr. Nye is a graduate of both Dartmouth College and Dartmouth's Amos Tuck School of Business Administration, where he received his MBA.

Jay Venkatesan is a Director of Brookside Captial. Prior to joining Brookside Capital in 2002, Dr. Venkatesan held senior executive positions at two start-up healthcare companies. Earlier in his career, he worked at Patricof & Co. Ventures with a focus on life sciences investments. He also spent several years at McKinsey & Company where he consulted to companies in the pharmaceutical, media, and information technology industries. Dr. Venkatesan received an M.D. from the University of Pennsylvania School of Medicine, an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College

Key Consultants

Paul Teirstein, MD Dr. Teirstein is Director of Interventional Cardiology and founder of the interventional cardiology program at Scripps Clinic in La Jolla, CA. He previously completed a fellowship in stents, atherectomy and lasers at the National Institutes of Health after completing a fellowship in Cardiology at Stanford University and as a fellow in complex angioplasty at the Mid-America Heart Institute in Kansas City, MO. Dr. Teirstein received his MD from Mount Sinai School of Medicine in New York and performed his internship and residency in internal medicine at the Brigham and Women's Hospital in Boston, MA.

Joachim Kohn Professor Kohn is a Board of Governors Professor of Chemistry and Chemical Biology at Rutgers University and an Adjunct Associate Professor of Orthopedics at the New Jersey Medical School. He currently serves as director of the New Jersey Center for Biomaterials and is a member of the board of governors of the Association of Institutions for Materials Science (AIMS). He is a fellow of the American Institute for Medical and Biological Engineering (AIMBE) and served as the secretary-treasurer of the Society for Biomaterials. He is the principal investigator of an NIH funded postdoctoral training program in tissue engineering and implant science. His research interests focus on the development of new biomaterials for prostheses, implantable drug or gene delivery systems, and tissue regeneration scaffolds. He has published 167 scientific manuscripts and reviews, and holds 31 patents.

Moni Stein, MD, FSIR. Dr. Stein is a Fellow of the Society of Vascular and Interventional Radiology and currently practices Interventional Radiology in Dublin, Ohio. He previously served as Associate Professor of Interventional Radiology at the University of California at Davis. Dr. Stein received his MD from and performed his internship and residency in diagnostic radiology at the University of Toronto. He then completed his fellowship training in Vascular and Interventional Radiology at The University of California, San Francisco.

REVA Medical, Inc. Raises $42 Million in Private Financing

SAN DIEGO, CA (December 10, 2007) – REVA Medical, Inc., a company developing novel bioresorbable stents to treat arterial disease, today announced it has raised $42 million in a private financing led by Cerberus Capital Management and Brookside Capital, an affiliate of Bain Capital.

Click to Read More

REVA Medical Announces Enrollment of First Patients in the RESORB Clinical Trial

Novel Bioresorbable Coronary Stent Begins Clinical Evaluation

SAN DIEGO, CA (June 26, 2007) – REVA Medical, Inc. today announced enrollment of the first patients in a first-in-man clinical trial designed to evaluate the safety of the REVA Bioresorbable Coronary Stent for the treatment of coronary artery disease.

Click to Read More

IYIA Technologies, Inc., SeQual And REVA Medical Win Awards At BIOCOM's DeviceFest

SAN DIEGO, Nov. 9 /PRNewswire/ -- IYIA Technologies, SeQual, and Reva Medical were recognized for their innovative new medical technologies at BIOCOM's First Annual DeviceFest, sponsored by Mentus Life Science.

Click to Read More

BOSTON SCIENTIFIC ANNOUNCES STRATEGIC ALLIANCE WITH REVA MEDICAL, INC.

Natick, MA (November 16, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has made an equity investment in - and secured an exclusive option to purchase - REVA Medical, Inc., a privately held company located in San Diego.

Click to Read More

REVA Medical, Inc. and the New Jersey Center for Biomaterials collaborate to develop the first fully bioreabsorbable polymer drug delivery stent that is visible by X-ray

San Diego, CA / September 15, 2003 / -- REVA Medical, Inc. and the New Jersey Center for Biomaterials have joined forces to develop the first bioreabsorbable polymer drug-delivery stent that is visible by X-ray radiography/fluoroscopy. X-ray visibility is necessary for placement accuracy and continued monitoring of the device after implantation.

Click to Read More